Reply to Sun : circGASP: A New Clinical Biomarker for Idiopathic Pulmonary Hypertension?
作者信息
Sun Yuan-Yuan, Wang Lan, Liu Jin-Ming, Yuan Ping
机构信息
Shanghai Pulmonary Hospital Affiliated to Tongji University Shanghai, China.
出版信息
Am J Respir Crit Care Med. 2022 Jan 15;205(2):254. doi: 10.1164/rccm.202108-1905LE.
Abstract
摘要
相似文献
1
Reply to Sun : circGASP: A New Clinical Biomarker for Idiopathic Pulmonary Hypertension?
Am J Respir Crit Care Med. 2022 Jan 15;205(2):254. doi: 10.1164/rccm.202108-1905LE.
2
circGSAP: A New Clinical Biomarker for Idiopathic Pulmonary Hypertension?
Am J Respir Crit Care Med. 2022 Jan 15;205(2):252-253. doi: 10.1164/rccm.202108-1868LE.
3
Questions Regarding the Value of CCL21 as a Potential Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Hoffmann-Vold et al.
Arthritis Rheumatol. 2019 Apr;71(4):653-654. doi: 10.1002/art.40743. Epub 2019 Mar 1.
4
Insufficient Evidence to Consider CCL21 a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Hoffmann-Vold et al.
Arthritis Rheumatol. 2019 Apr;71(4):654-655. doi: 10.1002/art.40819. Epub 2019 Mar 2.
5
Reply to Ning : More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension.
Am J Respir Crit Care Med. 2020 Feb 1;201(3):389-391. doi: 10.1164/rccm.201909-1800LE.
6
Reply to Weatherald : Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
Am J Respir Crit Care Med. 2021 Feb 15;203(4):525-526. doi: 10.1164/rccm.202010-3834LE.
7
Reply to Chen : BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?
Am J Respir Crit Care Med. 2020 May 15;201(10):1313-1314. doi: 10.1164/rccm.202001-0059LE.
8
Signals and signposts: Biomarkers in IPF and PAH at the crossroads of clinical relevance.
Respirology. 2019 Nov;24(11):1044-1045. doi: 10.1111/resp.13694. Epub 2019 Sep 5.
9
Reply.
Arthritis Rheumatol. 2019 Apr;71(4):655-656. doi: 10.1002/art.40816. Epub 2019 Mar 2.
10
[Diagnosis of idiopathic pulmonary arterial hypertension by "3P" algorithm].
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):621-625. doi: 10.3760/cma.j.cn112148-20200228-00140.
引用本文的文献
1
CircGSAP alleviates pulmonary microvascular endothelial cells dysfunction in pulmonary hypertension via regulating miR-27a-3p/BMPR2 axis.
Respir Res. 2022 Nov 19;23(1):322. doi: 10.1186/s12931-022-02248-7.
本文引用的文献
1
Nuclear export and translation of circular repeat-containing intronic RNA in C9ORF72-ALS/FTD.
Nat Commun. 2021 Aug 13;12(1):4908. doi: 10.1038/s41467-021-25082-9.
2
Impact of circGSAP in Peripheral Blood Mononuclear Cells on Idiopathic Pulmonary Arterial Hypertension.
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1579-1583. doi: 10.1164/rccm.202005-2052LE.
3
Circ- Serves as an Sponge to Regulate Myo10 (Myosin 10) and Promote Pulmonary Artery Smooth Muscle Proliferation.
Hypertension. 2020 Mar;75(3):668-679. doi: 10.1161/HYPERTENSIONAHA.119.13715. Epub 2020 Feb 3.
4
Molecular Mechanisms Driving mRNA Degradation by mA Modification.
Trends Genet. 2020 Mar;36(3):177-188. doi: 10.1016/j.tig.2019.12.007. Epub 2020 Jan 18.
5
The biogenesis, biology and characterization of circular RNAs.
Nat Rev Genet. 2019 Nov;20(11):675-691. doi: 10.1038/s41576-019-0158-7. Epub 2019 Aug 8.
6
Circular RNA Expression: Its Potential Regulation and Function.
Trends Genet. 2016 May;32(5):309-316. doi: 10.1016/j.tig.2016.03.002. Epub 2016 Apr 2.
Zotero 插件